Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.08
AMRI's Cash-to-Debt is ranked lower than
97% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. AMRI: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
AMRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 3.46 Max: 1216.19
Current: 0.08
0.08
1216.19
Equity-to-Asset 0.25
AMRI's Equity-to-Asset is ranked lower than
85% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRI: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
AMRI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.79 Max: 0.96
Current: 0.25
0.25
0.96
Piotroski F-Score: 2
Altman Z-Score: 1.04
Beneish M-Score: -2.61
WACC vs ROIC
8.87%
-0.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -3.29
AMRI's Operating Margin % is ranked higher than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. AMRI: -3.29 )
Ranked among companies with meaningful Operating Margin % only.
AMRI' s Operating Margin % Range Over the Past 10 Years
Min: -36.35  Med: 1.19 Max: 11.32
Current: -3.29
-36.35
11.32
Net Margin % -12.30
AMRI's Net Margin % is ranked higher than
66% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. AMRI: -12.30 )
Ranked among companies with meaningful Net Margin % only.
AMRI' s Net Margin % Range Over the Past 10 Years
Min: -31.74  Med: -1.54 Max: 8.97
Current: -12.3
-31.74
8.97
ROE % -23.80
AMRI's ROE % is ranked higher than
59% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. AMRI: -23.80 )
Ranked among companies with meaningful ROE % only.
AMRI' s ROE % Range Over the Past 10 Years
Min: -23.94  Med: -1.72 Max: 6.22
Current: -23.8
-23.94
6.22
ROA % -7.05
AMRI's ROA % is ranked higher than
70% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. AMRI: -7.05 )
Ranked among companies with meaningful ROA % only.
AMRI' s ROA % Range Over the Past 10 Years
Min: -17.99  Med: -1.15 Max: 5.29
Current: -7.05
-17.99
5.29
ROC (Joel Greenblatt) % -4.21
AMRI's ROC (Joel Greenblatt) % is ranked higher than
75% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. AMRI: -4.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.54  Med: 1.48 Max: 13.51
Current: -4.21
-35.54
13.51
3-Year Revenue Growth Rate 24.40
AMRI's 3-Year Revenue Growth Rate is ranked higher than
75% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. AMRI: 24.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 8.5 Max: 78
Current: 24.4
-1.6
78
3-Year EBITDA Growth Rate -10.40
AMRI's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AMRI: -10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.6  Med: 9.55 Max: 60.9
Current: -10.4
-48.6
60.9
GuruFocus has detected 5 Warning Signs with Albany Molecular Research Inc $AMRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRI's 10-Y Financials

Financials (Next Earnings Date: 2017-05-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMRI Guru Trades in Q1 2016

Jim Simons 323,242 sh (+42.84%)
Chuck Royce 1,079,469 sh (+9.46%)
Ken Fisher 203,450 sh (unchged)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

AMRI Guru Trades in Q2 2016

Paul Tudor Jones 12,500 sh (New)
Chuck Royce 1,183,969 sh (+9.68%)
Murray Stahl 56,000 sh (unchged)
Ken Fisher 203,450 sh (unchged)
Jim Simons 117,942 sh (-63.51%)
» More
Q3 2016

AMRI Guru Trades in Q3 2016

Jim Simons 347,242 sh (+194.42%)
Paul Tudor Jones 14,744 sh (+17.95%)
Chuck Royce 1,254,296 sh (+5.94%)
Murray Stahl 56,000 sh (unchged)
Ken Fisher 157,794 sh (-22.44%)
» More
Q4 2016

AMRI Guru Trades in Q4 2016

Jim Simons 357,900 sh (+3.07%)
Chuck Royce 1,290,911 sh (+2.92%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 80,589 sh (-48.93%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:CRSP, NAS:VSAR, NAS:EDIT, NAS:OMER, NAS:NDRM, NAS:TGTX, NAS:MGNX, NAS:ANIK, NAS:VNDA, NAS:ACOR, NAS:INSY, NYSE:MYOV, NAS:RGNX, NAS:RVNC, OTCPK:SXMDF, NAS:CYTK, NAS:KERX, NAS:ADRO, OTCPK:IPHYF, NAS:CTMX » details
Traded in other countries:AYM.Germany,
Headquarter Location:USA
Albany Molecular Research Inc is a contract research and manufacturing organization providing customers drug discovery, development and manufacturing services.

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Ratios

vs
industry
vs
history
Forward PE Ratio 13.76
AMRI's Forward PE Ratio is ranked higher than
77% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. AMRI: 13.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.27
AMRI's PB Ratio is ranked higher than
74% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AMRI: 2.27 )
Ranked among companies with meaningful PB Ratio only.
AMRI' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.2 Max: 3.09
Current: 2.27
0.29
3.09
PS Ratio 1.04
AMRI's PS Ratio is ranked higher than
95% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AMRI: 1.04 )
Ranked among companies with meaningful PS Ratio only.
AMRI' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.39 Max: 3.06
Current: 1.04
0.32
3.06
Price-to-Operating-Cash-Flow 20.98
AMRI's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. AMRI: 20.98 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMRI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.93  Med: 15.93 Max: 320.75
Current: 20.98
4.93
320.75
EV-to-EBIT -63.51
AMRI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AMRI: -63.51 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRI' s EV-to-EBIT Range Over the Past 10 Years
Min: -81  Med: 20.65 Max: 1112.9
Current: -63.51
-81
1112.9
EV-to-EBITDA 37.41
AMRI's EV-to-EBITDA is ranked lower than
75% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AMRI: 37.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.8  Med: 10.3 Max: 56
Current: 37.41
-39.8
56
Current Ratio 2.24
AMRI's Current Ratio is ranked lower than
70% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AMRI: 2.24 )
Ranked among companies with meaningful Current Ratio only.
AMRI' s Current Ratio Range Over the Past 10 Years
Min: 2.24  Med: 5.16 Max: 17.42
Current: 2.24
2.24
17.42
Quick Ratio 1.29
AMRI's Quick Ratio is ranked lower than
79% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AMRI: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
AMRI' s Quick Ratio Range Over the Past 10 Years
Min: 1.29  Med: 4.31 Max: 17.25
Current: 1.29
1.29
17.25
Days Inventory 107.67
AMRI's Days Inventory is ranked higher than
58% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. AMRI: 107.67 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s Days Inventory Range Over the Past 10 Years
Min: 57.53  Med: 63.97 Max: 106.89
Current: 107.67
57.53
106.89
Days Sales Outstanding 92.65
AMRI's Days Sales Outstanding is ranked lower than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AMRI: 92.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.89  Med: 64.89 Max: 100.17
Current: 92.65
43.89
100.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.70
AMRI's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. AMRI: -10.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.7  Med: -0.6 Max: 2.8
Current: -10.7
-10.7
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.97
AMRI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
54% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. AMRI: 2.97 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMRI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.5  Med: 0.83 Max: 3.52
Current: 2.97
0.5
3.52
Price-to-Median-PS-Value 0.75
AMRI's Price-to-Median-PS-Value is ranked higher than
73% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AMRI: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.38 Max: 20.07
Current: 0.75
0.3
20.07
Earnings Yield (Greenblatt) % -1.57
AMRI's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AMRI: -1.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 3.8 Max: 16.5
Current: -1.57
0.1
16.5
Forward Rate of Return (Yacktman) % 17.46
AMRI's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. AMRI: 17.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMRI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.3  Med: 0.7 Max: 20.9
Current: 17.46
-17.3
20.9

More Statistics

Revenue (TTM) (Mil) $570.4
EPS (TTM) $ -1.82
Beta1.36
Short Percentage of Float23.86%
52-Week Range $12.45 - 19.35
Shares Outstanding (Mil)42.94

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 738 797
EPS ($) 1.15 1.50
EPS without NRI ($) 1.15 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Can Feb 08 2016 
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 

More From Other Websites
ETFs with exposure to Albany Molecular Research, Inc. : April 7, 2017 Apr 07 2017
AMRI Receives CMO Leadership Awards for Excellence Mar 22 2017
3 Biotech Stocks to Buy in March Mar 10 2017
AMRI to Present at Barclays Global Healthcare Conference Mar 03 2017
Albany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22,... Feb 22 2017
Albany Molecular Research 4Q Net Misses Street Feb 22 2017
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US :... Feb 22 2017
Edited Transcript of AMRI earnings conference call or presentation 21-Feb-17 1:30pm GMT Feb 21 2017
Albany Molecular Research posts 4Q loss Feb 21 2017
AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize... Feb 21 2017
AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook Feb 21 2017
AMRI Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call Feb 15 2017
AMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery Feb 07 2017
Albany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : January 20, 2017 Jan 20 2017
Albany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US :... Jan 19 2017
AMRI CEO to Present at 35th Annual J.P. Morgan Healthcare Conference Dec 13 2016
Is Instructure Inc (INST) A Good Stock to Buy? Dec 12 2016
Is Albany Molecular Research, Inc. (AMRI) A Good Stock To Buy? Dec 05 2016
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US :... Dec 02 2016
AMRI Announces API Supply Agreement with Shire Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)